Investor Presentaiton
IDEAYA's Potential First-in-Class Precision Medicine Oncology Pipeline
Building an Industry Leading and Fully-Integrated Biotechnology Company
Precision Medicine Pipeline
Modality/Indication
Collaborations
Commercial (IDEAYA)
Biomarker
Pre-
clinical
IND
Enabling
Phase 1
Phase 2
Potential
Registrational
Program Goals / Achievements
+CMET¹ Combination
1L HLA-A2(-) MUM
GNAQ/11
Phase 2 (AA) / Phase 3
Registrational Trial * Initiated
Darovasertib
+CMET¹ Combination
GNAQ/11
PKC
HLA-A2(+) MUM ^
Pfizer (1)
HLA-A2(+) Clinical Trial ^
WW Commercial Rights
(Neo) Adjuvant UM
GNAQ/11
Monotherapy
Solid Tumors
MTAP
IDE397
MAT2A
Combinations
MTAP
Solid Tumors
IDE161
PARG
Breast, Ovarian
HRD
Cancers
GSK101
+Niraparib Combo4
Pol Theta Helicase
Solid Tumors
HR
Mutations
Phase 2 Clinical Trial Initiated
IST Update Q4 2023
Phase 2 Monotherapy Expansion in NSCLC,
Bladder, Esophageal and Gastric Cancers
Phase 1 IDE397 + AMG 193 (PRMT5¡MTA)
Amgen-Sponsored Combination Study Initiated
Phase 1 Monotherapy Expansion in HRD Tumors
Program Updates H2 2023
Phase 1 GSK101 (IDE705) + Niraparib
Earned $7M Milestone IND Clearance
WW Commercial Rights
AMGEN (2)
CANCER
RESEARCH (3)
WW Commercial Rights
UK
WRN
Werner Helicase
Gl Cancers
High-MSI
Development Candidate H2 2023
Potential $3M Milestone IND-Enabling Studies
GSK (4)
GSK (4)
Global Royalties
US 50/50 Profit Share
Ex-US Royalties
Platform
Solid Tumors
Defined
Biomarkers
New Target / Biomarker Discovery & Validation
Drug Discovery / Translational Biology
WW Commercial Rights
9
+Integrated Phase 2/3 enables potential Accelerated Approval (AA, Phase 2) and potential Full Approval (Phase 3) based on FDA Type C Meeting Q1 2023
^ Targeting enrollment of additional HLA-A2(+) patients in a separate clinical trial (e.g., ongoing IDE196-001 Phase 2 clinical trial)
(1) Pursuant to Pfizer Clinical Trial Collaboration and Supply Agreements for Darovasertib/Crizotinib Combination in MUM; IDEAYA retains all Darovasertib Commercial Rights
(2) Pursuant to Amgen Clinical Trial Collaboration and Supply Agreement for IDE397 + AMG 193, an investigational MTA-cooperative PRMT5 inhibitor; Amgen will sponsor the study and the parties will jointly share external costs of the study
(3) Pursuant to CRUK Evaluation, Option and License Agreement; IDEAYA controls all PARG Commercial Rights
(4) Pursuant to GSK Collaboration, Option and License Agreement: Pole: Global Royalties; WRN: 50/50 US Profits + ex-US Royalties
MAT2A-methionine adenosyltransferase 2a, MTAP-methylthioadenosine phosphorylase, MTA-methylthioadenosine, PRMT5-protein arginine methyltransferase 5 (PRMT5), PARG= poly (ADP-ribose) glycohydrolase, DDT = DNA Damage Target, WRN = Werner Helicase,
Pole = DNA Polymerase Theta, HRD = homologous recombination deficiency, MSI = microsatellite instability, PKC = protein kinase C, MUM = metastatic uveal melanoma, UM = uveal melanoma, Crizo = crizotinib, NSCLC = non-small cell lung cancer, WW = worldwide,
HLA-A2(-) = HLA-A2*02:01 Negative; HLA-A2(+) = HLA-A2*02:01 Positive
= Target Program Milestones
IDEA A
BIOSCIENCESView entire presentation